Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.47 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944875 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL28451178 | 0.98 | SMN1; SMN2 (0.77) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL28451180 | 0.98 | SMN1; SMN2 (0.77) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL20323496 | 0.96 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL21061603 | 0.96 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL21061407 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL28450922 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL21061406 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL28450923 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2HPGDHTTALDH1A1POLB | |
| SCHEMBL2950453 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2HPGDHTTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORPORATION | 2021-11-11 | — | — | US | disclosed |
| EP-3558981-B1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2020-07-21 | — | — | US | disclosed |
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7605158-B2 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7375119-B2 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060287329-A1 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-12-21 | — | — | US | disclosed |
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1666478-A1 | CARBAMOYL-TYPE BENZOFURAN DERIVATIVES | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1666455-A1 | AMIDE TYPE CARBOXAMIDE DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717726-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | SMN1; SMN2 4744/4885HPGD 184/4885HTT 4876/4885 |
| US-20210347765-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | SMN1; SMN2 4744/4885HPGD 184/4885HTT 4876/4885 |
| US-20060287329-A1 | Amide type carboxamide derivative | F12, F11, F13A1 | SMN1; SMN2 3486/4885HPGD 3301/4885HTT 3874/4885 |
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | F12, F2, F3 | SMN1; SMN2 4587/4885HPGD 1853/4885HTT 2317/4885 |
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | SMN1; SMN2 4447/4885HPGD 431/4885HTT 3215/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | SMN1; SMN2 4744/4885HPGD 184/4885HTT 4876/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | SMN1; SMN2 4599/4885HPGD 196/4885HTT 4867/4885 |
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | SMN1; SMN2 4490/4885HPGD 600/4885HTT 3762/4885 |
| US-20200299280-A1 | PYRAN DERVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | SMN1; SMN2 4744/4885HPGD 184/4885HTT 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.